In pre-clinical studies of myeloproliferative neoplasms, Ruxolitinib inhibited the proliferation of JAK2 V617F-driven Ba/F3 cells that constitutively phosphorylate JAK2 [131]. Here, JAK2 is linked to myeloproliferative disorder.